{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T02:00:13Z","timestamp":1795053613888,"version":"4.10.2"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T00:00:00Z","timestamp":1654560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T00:00:00Z","timestamp":1654560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Mineralocorticoid receptor antagonists (MRAs) are widely used for chronic central serous chorioretinopathy (cCSCR), but their effectiveness remains unclear. This research was conducted to evaluate the efficacy of this drugs for cCSCR.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This is a review of randomized clinical trials (RCT) comparing MRAs to placebo in adults with cCSCR, using the effects of MRAs on best-corrected visual acuity (BCVA) and adverse events as primary outcomes and the effects of MRAs on anatomical parameters as secondary outcomes: central subfield thickness (CST), subretinal fluid height (SFH) and central choroidal thickness (CCT). Our all-language online search included Medline (via PubMed), Central, Embase, Lilacs, Ibecs, and RCT registers platforms, as late as May 2021. We used the Cochrane risk-of-bias tool (version 2) to assess the methodological quality of each study and synthesized the results in meta-analyses using a random-effects model.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The search identified 302 records, five of which were eligible, totaling 225 cCSCR patients (aged 45\u201362\u00a0years; M\/F ratio 3.1:1) treated for 1 to 12\u00a0months with spironolactone (50\u00a0mg\/day) or eplerenone (50\u00a0mg\/day) <jats:italic>vs.<\/jats:italic> placebo. Moderate-certainty evidence suggests MRAs result in little to no improvement in BCVA compared to placebo (SMD 0.22; 95% CI \u2212\u00a00.04 to 0.48; studies\u2009=\u20095; comparisons\u2009=\u20096; participants\u2009=\u2009218; I<jats:sup>2<\/jats:sup>\u2009=\u20090%). Very low-certainty evidence suggests that, when compared to placebo, MRAs have a very uncertain impact on adverse effects (no meta-analysis was performed), and CST (MD 18.1; 95% CI \u2212\u00a0113.04 to 76.84; participants\u2009=\u2009145; studies\u2009=\u20092; I<jats:sup>2<\/jats:sup>\u2009=\u200968%). MRAs also result in little to no difference in SFH (SMD \u2212\u00a00.35; 95% CI \u2212\u00a00.95 to 0.26; studies\u2009=\u20095; comparisons\u2009=\u20096; participants\u2009=\u2009221; I<jats:sup>2<\/jats:sup>\u2009=\u200976%; moderate certainty) and CCT (MD \u2212\u00a021.23; 95% CI \u2212\u00a064.69 to 22.24; participants\u2009=\u2009206; studies\u2009=\u20094; comparisons\u2009=\u20095; I<jats:sup>2<\/jats:sup>\u2009=\u200985%; low certainty).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>MRAs have little to no effect on BCVA. Evidence for adverse events and CST is very uncertain. MRAs also have little to no effect on SFH and CCT. These findings should be considered when prescribing MRAs for cCSCR.<\/jats:p>\n                <jats:p>This research was previous registration in the PROSPERO platform (CRD42020182601).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40942-022-00385-1","type":"journal-article","created":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T09:03:22Z","timestamp":1654592602000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Mineralocorticoid receptor antagonists for chronic central serous chorioretinopathy: systematic review and meta-analyses"],"prefix":"10.1186","volume":"8","author":[{"given":"Camila Q.","family":"Felipe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Luiza","family":"Biancardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinicius T.","family":"Civile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Carvas Junior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro D.","family":"Serracarbassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5556-8061","authenticated-orcid":false,"given":"Marcia K.","family":"Koike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,7]]},"reference":[{"issue":"1","key":"385_CR1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41433-018-0158-4","volume":"33","author":"CMG Cheung","year":"2019","unstructured":"Cheung CMG, Lee WK, Koizumi H, et al. Pachychoroid disease. Eye. 2019;33(1):14\u201333. https:\/\/doi.org\/10.1038\/s41433-018-0158-4.","journal-title":"Eye"},{"issue":"2","key":"385_CR2","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/j.1600-0420.2007.00889.x","volume":"86","author":"M Wang","year":"2008","unstructured":"Wang M, Munch IC, Hasler PW, et al. Central serous chorioretinopathy. Acta Ophthalmol. 2008;86(2):126\u201345. https:\/\/doi.org\/10.1111\/j.1600-0420.2007.00889.x.","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"385_CR3","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ophtha.2007.02.032","volume":"115","author":"AS Kitzmann","year":"2008","unstructured":"Kitzmann AS, Pulido JS, Diehl NN, et al. The Incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980\u20132002. Ophthalmology. 2008;115(1):169\u201373. https:\/\/doi.org\/10.1016\/j.ophtha.2007.02.032.","journal-title":"Ophthalmology"},{"key":"385_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2019.07.003","volume":"73","author":"TJ van Rijssen","year":"2019","unstructured":"van Rijssen TJ, van Dijk EHC, Yzer S, et al. Central serous chorioretinopathy: towards an evidence-based treatment guideline. Prog Retin Eye Res. 2019;73: 100770. https:\/\/doi.org\/10.1016\/j.preteyeres.2019.07.003.","journal-title":"Prog Retin Eye Res"},{"issue":"4","key":"385_CR5","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/aos.12779","volume":"94","author":"KH Wong","year":"2016","unstructured":"Wong KH, Lau KP, Chhablani J, et al. Central serous chorioretinopathy: what we have learnt so far. Acta Ophthalmol. 2016;94(4):321\u20135. https:\/\/doi.org\/10.1111\/aos.12779.","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"385_CR6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/IAE.0b013e318156777f","volume":"28","author":"WM Chan","year":"2008","unstructured":"Chan WM, Lai TYY, Lai RYK, et al. Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: one-year results of a prospective study. Retina. 2008;28(1):85\u201393. https:\/\/doi.org\/10.1097\/IAE.0b013e318156777f.","journal-title":"Retina"},{"issue":"2","key":"385_CR7","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.ajo.2009.08.026","volume":"149","author":"M Reibaldi","year":"2010","unstructured":"Reibaldi M, Cardascia N, Longo A, et al. Standard-Fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial. Am J Ophthalmol. 2010;149(2):307\u201315. https:\/\/doi.org\/10.1016\/j.ajo.2009.08.026.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"385_CR8","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/IAE.0b013e3181e378f2","volume":"31","author":"JY Shin","year":"2011","unstructured":"Shin JY, Woo SJ, Yu HG, et al. Comparison of efficacy and safety between half-fluence and full-fluence photodynamic therapy for chronic central serous chorioretinopathy. Retina. 2011;31(1):119\u201326. https:\/\/doi.org\/10.1097\/IAE.0b013e3181e378f2.","journal-title":"Retina"},{"issue":"4","key":"385_CR9","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.ophtha.2018.12.048","volume":"126","author":"S Mrejen","year":"2019","unstructured":"Mrejen S, Balaratnasingam C, Kaden TR, et al. Long-term Visual outcomes and causes of vision loss in chronic central serous chorioretinopathy. Ophthalmology. 2019;126(4):576\u201388. https:\/\/doi.org\/10.1016\/j.ophtha.2018.12.048.","journal-title":"Ophthalmology"},{"issue":"2","key":"385_CR10","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/J.SURVOPHTHAL.2012.07.004","volume":"58","author":"B Nicholson","year":"2013","unstructured":"Nicholson B, Noble J, Forooghian F, et al. Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol. 2013;58(2):103\u201326. https:\/\/doi.org\/10.1016\/J.SURVOPHTHAL.2012.07.004.","journal-title":"Surv Ophthalmol"},{"issue":"2","key":"385_CR11","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.1442-9071.2012.02847.x","volume":"41","author":"G Quin","year":"2013","unstructured":"Quin G, Liew G, Van HI, et al. Diagnosis and interventions for central serous chorioretinopathy: review and update. Clin Exp Ophthalmol. 2013;41(2):187\u2013200. https:\/\/doi.org\/10.1111\/j.1442-9071.2012.02847.x.","journal-title":"Clin Exp Ophthalmol"},{"key":"385_CR12","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1097\/IAE.0000000000001005","volume":"36","author":"JK Luttrull","year":"2016","unstructured":"Luttrull JK. Low-intensity\/high-density subthreshold diode micropulse laser for central serous chorioretinopathy. Retina. 2016;36:1658\u201363. https:\/\/doi.org\/10.1097\/IAE.0000000000001005.","journal-title":"Retina"},{"key":"385_CR13","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/eye.2014.315","volume":"29","author":"NK Yadav","year":"2015","unstructured":"Yadav NK, Jayadev C, Mohan A, et al. Subthreshold micropulse yellow laser (577 nm) in chronic central serous chorioretinopathy: safety profile and treatment outcome. Eye. 2015;29:258\u201364. https:\/\/doi.org\/10.1038\/eye.2014.315.","journal-title":"Eye"},{"key":"385_CR14","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1007\/s00417-015-2965-7","volume":"253","author":"JY Kim","year":"2015","unstructured":"Kim JY, Park HS, Kim SY. Short-term efficacy of subthreshold micropulse yellow laser (577-nm) photocoagulation for chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2015;253:2129\u201335. https:\/\/doi.org\/10.1007\/s00417-015-2965-7.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"385_CR15","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1097\/IAE.0000000000000285","volume":"35","author":"KJ Malik","year":"2015","unstructured":"Malik KJ, Sampat KM, Mansouri A, et al. Low-intensity\/highdensity subthreshold micropulse diode laser for chronic central serous chorioretinopathy. Retina. 2015;35:532\u20136. https:\/\/doi.org\/10.1097\/IAE.0000000000000285.","journal-title":"Retina"},{"key":"385_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2017-311291","author":"JA Roca","year":"2018","unstructured":"Roca JA, Wu L, Fromow-Guerra J, et al. Yellow (577 nm) micropulse laser versus half-dose verteporfin photodynamic therapy in eyes with chronic central serous chorioretinopathy: results of the Pan-American Collaborative Retina Study (PACORES) Group. Br J Ophthalmol. 2018. https:\/\/doi.org\/10.1136\/bjophthalmol-2017-311291.","journal-title":"Br J Ophthalmol"},{"key":"385_CR17","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/eye.2017.293","volume":"32","author":"A Arsan","year":"2018","unstructured":"Arsan A, Kanar HS, Sonmez A. Visual outcomes and anatomic changes after sub-threshold micropulse yellow laser (577-nm) treatment for chronic central serous chorioretinopathy: long-term follow-up. Eye. 2018;32:726\u201333. https:\/\/doi.org\/10.1038\/eye.2017.293.","journal-title":"Eye"},{"issue":"10","key":"385_CR18","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/j.ophtha.2018.04.021","volume":"125","author":"EHC van Dijk","year":"2018","unstructured":"van Dijk EHC, Fauser S, Breukink MB, et al. Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: The place trial. Ophthalmology. 2018;125(10):1547\u201355. https:\/\/doi.org\/10.1016\/j.ophtha.2018.04.021.","journal-title":"Ophthalmology"},{"issue":"9","key":"385_CR19","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.3390\/jcm8091398","volume":"8","author":"M Gaw\u0119cki","year":"2019","unstructured":"Gaw\u0119cki M, Jaszczuk-Maciejewska A, Jurska-Ja\u015bko A, et al. Transfoveal micropulse laser treatment of central serous chorioretinopathy within six months of disease onset. J Clin Med. 2019;8(9):1398. https:\/\/doi.org\/10.3390\/jcm8091398.","journal-title":"J Clin Med"},{"issue":"7","key":"385_CR20","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1172\/JCI61427DS1","volume":"122","author":"M Zhao","year":"2012","unstructured":"Zhao M, C\u00e9l\u00e9rier I, Bousquet E, et al. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J Clin Invest. 2012;122(7):2672\u20139. https:\/\/doi.org\/10.1172\/JCI61427DS1.","journal-title":"J Clin Invest"},{"issue":"10","key":"385_CR21","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1007\/s00417-016-3417-8","volume":"254","author":"EHC van Dijk","year":"2016","unstructured":"van Dijk EHC, Nijhoff MF, de Jong EK, et al. Central serous chorioretinopathy in primary hyperaldosteronism. Graefe\u2019s Arch Clin Exp Ophthalmol. 2016;254(10):2033\u201342. https:\/\/doi.org\/10.1007\/s00417-016-3417-8.","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"385_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2019.107754","volume":"187","author":"E Bousquet","year":"2019","unstructured":"Bousquet E, Zhao M, Daruich A, et al. Mineralocorticoid antagonists in the treatment of central serous chorioretinopathy: review of the pre-clinical and clinical evidence. Exp Eye Res. 2019;187: 107754. https:\/\/doi.org\/10.1016\/j.exer.2019.107754.","journal-title":"Exp Eye Res"},{"issue":"12","key":"385_CR23","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1097\/IAE.0000000000000614","volume":"35","author":"E Bousquet","year":"2015","unstructured":"Bousquet E, Beydoun T, Rothschild PR, et al. Spironolactone for nonresolving central serous chorioretinopathy: a randomized controlled crossover study. Retina. 2015;35(12):2505\u201315.","journal-title":"Retina"},{"issue":"10","key":"385_CR24","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1097\/IAE.0b013e318297a07a","volume":"33","author":"E Bousquet","year":"2013","unstructured":"Bousquet E, Beydoun T, Zhao M, et al. Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study. Retina. 2013;33(10):2096\u2013102. https:\/\/doi.org\/10.1097\/IAE.0b013e318297a07a.","journal-title":"Retina"},{"issue":"6","key":"385_CR25","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1097\/iae.0000000000001303","volume":"37","author":"R Gergely","year":"2017","unstructured":"Gergely R, Kov\u00e1cs I, Schneider M, et al. Mineralocorticoid receptor antagonist treatment in bilateral chronic central serous chorioretinopathy: a comparative study of exudative and nonexudative fellow eyes. Retina. 2017;37(6):1084\u201391. https:\/\/doi.org\/10.1097\/iae.0000000000001303.","journal-title":"Retina"},{"issue":"7","key":"385_CR26","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3928\/23258160-20180628-03","volume":"49","author":"B Rajesh","year":"2018","unstructured":"Rajesh B, Agrawal H, Peguda HK, et al. Predictors of outcome during eplerenone therapy in chronic central serous chorioretinopathy: a prospective, open-label pilot clinical study. Ophthalmic Surg Lasers Imaging Retina. 2018;49(7):479\u201386. https:\/\/doi.org\/10.3928\/23258160-20180628-03.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"7","key":"385_CR27","doi-asserted-by":"publisher","first-page":"e610","DOI":"10.1111\/aos.13491","volume":"95","author":"R Schwartz","year":"2017","unstructured":"Schwartz R, Habot-Wilner Z, Martinez MR, et al. Eplerenone for chronic central serous chorioretinopathy-a randomized controlled prospective study. Acta Ophthalmol. 2017;95(7):e610\u20138. https:\/\/doi.org\/10.1111\/aos.13491.","journal-title":"Acta Ophthalmol"},{"issue":"5","key":"385_CR28","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1097\/IAE.0000000000001649","volume":"38","author":"E Rahimy","year":"2018","unstructured":"Rahimy E, Pitcher JD, Hsu J, et al. A randomized double-blind placebo-control pilot study of eplerenone for the treatment of central serous chorioretinopathy (ecselsior). Retina. 2018;38(5):962\u20139. https:\/\/doi.org\/10.1097\/IAE.0000000000001649.","journal-title":"Retina"},{"issue":"5","key":"385_CR29","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s10792-016-0377-2","volume":"37","author":"F Pichi","year":"2017","unstructured":"Pichi F, Carrai P, Ciardella A, et al. Comparison of two mineralocorticosteroid receptor antagonists for the treatment of central serous chorioretinopathy. Int Ophthalmol. 2017;37(5):1115\u201325. https:\/\/doi.org\/10.1007\/s10792-016-0377-2.","journal-title":"Int Ophthalmol"},{"issue":"10220","key":"385_CR30","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S0140-6736(19)32981-2","volume":"395","author":"A Lotery","year":"2020","unstructured":"Lotery A, Sivaprasad S, O\u2019Connell A, et al. Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. Lancet. 2020;395(10220):294\u2013303. https:\/\/doi.org\/10.1016\/S0140-6736(19)32981-2.","journal-title":"Lancet"},{"issue":"12","key":"385_CR31","doi-asserted-by":"publisher","first-page":"CD011841","DOI":"10.1002\/14651858.CD011841.pub2","volume":"2015","author":"M Salehi","year":"2015","unstructured":"Salehi M, Wenick AS, Law HA, et al. Interventions for central serous chorioretinopathy: a network meta-analysis. Cochrane Database Syst Rev. 2015;2015(12):CD011841. https:\/\/doi.org\/10.1002\/14651858.CD011841.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"385_CR32","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/s41433-020-01338-4","volume":"35","author":"J Duan","year":"2021","unstructured":"Duan J, Zhang Y, Zhang M. Efficacy and safety of the mineralocorticoid receptor antagonist treatment for central serous chorioretinopathy: a systematic review and meta-analysis. Eye. 2021;35(4):1102\u201310. https:\/\/doi.org\/10.1038\/s41433-020-01338-4.","journal-title":"Eye"},{"issue":"11","key":"385_CR33","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1007\/s10792-020-01479-1","volume":"40","author":"B Zhang","year":"2020","unstructured":"Zhang B, Chou Y, Zhao X, et al. Efficacy of mineralocorticoid receptor antagonist for central serous chorioretinopathy: a meta-analysis. Int Ophthalmol. 2020;40(11):2957\u201367. https:\/\/doi.org\/10.1007\/s10792-020-01479-1.","journal-title":"Int Ophthalmol"},{"issue":"2","key":"385_CR34","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.oret.2018.09.003","volume":"3","author":"SK Wang","year":"2019","unstructured":"Wang SK, Sun P, Tandias RM, et al. mineralocorticoid receptor antagonists in central serous chorioretinopathy: a meta-analysis of randomized controlled trials. Ophthalmol Retin. 2019;3(2):154\u201360. https:\/\/doi.org\/10.1016\/j.oret.2018.09.003.","journal-title":"Ophthalmol Retin"},{"key":"385_CR35","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"issue":"1","key":"385_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, et al. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):1\u201310. https:\/\/doi.org\/10.1186\/s13643-016-0384-4.","journal-title":"Syst Rev"},{"issue":"3","key":"385_CR37","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.ajo.2009.11.017","volume":"149","author":"LA Yannuzzi","year":"2010","unstructured":"Yannuzzi LA. Central serous chorioretinopathy: a personal perspective. Am J Ophthalmol. 2010;149(3):361\u20133. https:\/\/doi.org\/10.1016\/j.ajo.2009.11.017.","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"385_CR38","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1038\/eye.2010.130","volume":"24","author":"M Gemenetzi","year":"2010","unstructured":"Gemenetzi M, De Salvo G, Lotery AJ. Central serous chorioretinopathy: an update on pathogenesis and treatment. Eye. 2010;24(12):1743\u201356. https:\/\/doi.org\/10.1038\/eye.2010.130.","journal-title":"Eye"},{"issue":"10","key":"385_CR39","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1097\/IAE.0000000000001443","volume":"37","author":"A Daruich","year":"2017","unstructured":"Daruich A, Matet A, Marchionno L, et al. Acute central serous chorioretinopathy. Retina. 2017;37(10):1905\u201315. https:\/\/doi.org\/10.1097\/IAE.0000000000001443.","journal-title":"Retina"},{"key":"385_CR40","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/OPTH.S115685","volume":"11","author":"MB Breukink","year":"2016","unstructured":"Breukink MB, Dingemans AJ, den Hollander AI, et al. Chronic central serous chorioretinopathy: long-term follow-up and vision-related quality of life. Clin Ophthalmol. 2016;11:39\u201346. https:\/\/doi.org\/10.2147\/OPTH.S115685.","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"385_CR41","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12886-019-1171-5","volume":"19","author":"M Gaw\u0119cki","year":"2019","unstructured":"Gaw\u0119cki M, Jaszczuk-Maciejewska A, Jurska-Ja\u015bko A, et al. Impairment of visual acuity and retinal morphology following resolved chronic central serous chorioretinopathy. BMC Ophthalmol. 2019;19(1):160. https:\/\/doi.org\/10.1186\/s12886-019-1171-5.","journal-title":"BMC Ophthalmol"},{"issue":"11","key":"385_CR42","doi-asserted-by":"publisher","first-page":"3429","DOI":"10.3390\/jcm9113429","volume":"9","author":"M Gaw\u0119cki","year":"2020","unstructured":"Gaw\u0119cki M, Jaszczuk A, Grzybowski A. Short term presence of subretinal fluid in central serous chorioretinopathy affects retinal thickness and function. J Clin Med. 2020;9(11):3429. https:\/\/doi.org\/10.3390\/jcm9113429.","journal-title":"J Clin Med"},{"key":"385_CR43","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ajo.2016.02.012","volume":"165","author":"E Bousquet","year":"2016","unstructured":"Bousquet E, Dhundass M, Lehmann M, et al. Shift Work: a risk factor for central serous chorioretinopathy. Am J Ophthalmol. 2016;165:23\u20138. https:\/\/doi.org\/10.1016\/j.ajo.2016.02.012.","journal-title":"Am J Ophthalmol"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-022-00385-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-022-00385-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-022-00385-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T21:10:20Z","timestamp":1654636220000},"score":1,"resource":{"primary":{"URL":"https:\/\/journalretinavitreous.biomedcentral.com\/articles\/10.1186\/s40942-022-00385-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,7]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["385"],"URL":"https:\/\/doi.org\/10.1186\/s40942-022-00385-1","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,7]]},"assertion":[{"value":"24 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34"}}